| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Medicine, University College London, London, United Kingdom; and
Department of Histopathology, Faculty of Medicine, Imperial College, London, United Kingdom
Systemic lupus erythematosus is a multisystem autoimmune disease characterized by a wide range of immunological abnormalities that underlie the loss of tolerance. In this study we show that administration of atorvastatin to lupus-prone NZB/W F1 mice resulted in a significant reduction in serum IgG anti-dsDNA Abs and decreased proteinuria. Histologically, the treatment was associated with reduced glomerular Ig deposition and less glomerular injury. Disease improvement was paralleled by decreased expression of MHC class II on monocytes and B lymphocytes and reduced expression of CD80 and CD86 on B lymphocytes. Consequent upon this inhibition of Ag presentation, T cell proliferation was strongly impaired by atorvastatin in vitro and in vivo. A significant decrease in MHC class II expression was also observed in the target organ of lupus disease (i.e., the glomerulus). Serum cholesterol in atorvastatin-treated lupus mice fell to the level found in young NZB/W mice before disease onset. This is the first demonstration that atorvastatin can delay the progression of a spontaneous autoimmune disease and may specifically benefit patients with systemic lupus erythematosus.
This article has been cited by other articles:
|
|
 |
|
  R. Escarcega, M Garcia-Carrasco, L. Jara, and R Cervera Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality Lupus, April 1, 2009; 18(5): 383 - 386. [PDF]
|
|
|
|
 |
|
 M Imamura, K Okunishi, H Ohtsu, K Nakagome, H Harada, R Tanaka, K Yamamoto, and M Dohi Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung Thorax, January 1, 2009; 64(1): 44 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway J. Immunol., September 1, 2008; 181(5): 3524 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Belizna, A Lartigue, J Favre, D Gilbert, F Tron, H Levesque, C Thuillez, and V Richard Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome? Lupus, March 1, 2008; 17(3): 185 - 194. [Abstract] [PDF]
|
|
|
|
 |
|
 S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tenbrock, Y.-T. Juang, V. C. Kyttaris, and G. C. Tsokos Altered signal transduction in SLE T cells Rheumatology, October 1, 2007; 46(10): 1525 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Blank, M. Schiller, S. Krienke, F. Busse, B. Schatz, A. D. Ho, J. R. Kalden, and H.-M. Lorenz Atorvastatin Inhibits T Cell Activation through 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase without Decreasing Cholesterol Synthesis J. Immunol., September 15, 2007; 179(6): 3613 - 3621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Schneider Exploring new territory: considering the future Lupus, March 1, 2007; 16(3): 221 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Tanaka, C. M. Porter, J. A. Horvath-Arcidiacono, and E. T. Bloom Lipophilic statins suppress cytotoxicity by freshly isolated natural killer cells through modulation of granule exocytosis Int. Immunol., February 1, 2007; 19(2): 163 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Jury, D. A. Isenberg, C. Mauri, and M. R. Ehrenstein Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus J. Immunol., November 15, 2006; 177(10): 7416 - 7422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aprahamian, R. Bonegio, J. Rizzo, H. Perlman, D. J. Lefer, I. R. Rifkin, and K. Walsh Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol., September 1, 2006; 177(5): 3028 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Riboldi, M Gerosa, and P L Meroni Statins and autoimmune diseases Lupus, September 1, 2005; 14(9): 765 - 768. [Abstract] [PDF]
|
|
|
|
|
|
E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Ehrenstein, E. C. Jury, and C. Mauri Statins for Atherosclerosis -- As Good as It Gets? N. Engl. J. Med., January 6, 2005; 352(1): 73 - 75. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
